Background Introduction of human papillomavirus (HPV) vaccination in settings with the
highest burden of HPV is not universal, partly because of the absence of quantitative …

Summary Background The Papillomavirus Rapid Interface for Modelling and Economics
(PRIME) has been used around the world to assess the health impact and cost-effectiveness …

With a human papillomavirus (HPV) vaccine soon to become available for widespread use,
several studies have modelled the cost-effectiveness of vaccination. These pioneer studies …

Background Since 2006, many countries have implemented publicly funded human
papillomavirus (HPV) immunisation programmes. However, global estimates of the extent …

Cost-effectiveness analysis (CEA) is a well-known, but resource intensive, method for
comparing the costs and health outcomes of health interventions. To build on available …

Background Introduction of human papillomavirus (HPV) vaccination has been slow in low-
income and middle-income countries (LMICs) because of resource constraints and …

Background Mortality rates from cervical cancer demonstrate deep inequality in health
between richer and poorer populations. Over 310 000 women died of this preventable …

Background Although guidelines for prophylactic human papillomavirus (HPV) vaccination
recommend two doses for girls ages 9–14 years, several studies have demonstrated similar …

Background Given the accumulating evidence that one-dose vaccination could provide high
and sustained protection against human papillomavirus (HPV) infection and related …

Background: With promising efficacy results from randomized control trials of human
papillomavirus (HPV) vaccines and the availability of new screening paradigms …